权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Rapid Response Agents Against Filovirus Outbreaks Using Vectored Immunoprophylaxis

使用载体免疫预防针对丝状病毒爆发的快速反应剂

基本信息

批准号：
9200868
负责人：
Larry Zeitlin
金额：
$ 24.02万
依托单位：
MAPP BIOPHARMACEUTICAL, INC.
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-08-01 至 2017-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9200868
关键词：
Address Animal Model Animals Antibodies Bioterrorism Categories Cavia Communicable Diseases DNA Democratic Republic of the Congo Dengue Virus Disease Outbreaks Ebola Vaccines Ebola virus Enzyme-Linked Immunosorbent Assay Epidemic Europe Filovirus Gene Therapy Agent Gene Transfer Genes Glycoproteins Goals Guinea HIV HIV Antibodies HIV prevention trial Head Health Personnel Human Immunofluorescence Immunologic Immunoprecipitation In Vitro Individual Infection Infectious Agent Injection of therapeutic agent International Investigation Kinetics Liberia Life Macaca Modeling Monoclonal Antibodies Mus Passive Immunization Pattern Phase Plasmids Population Prevention approach Production Reagent Reporting Sierra Leone System Technology Testing Therapeutic Time United States Vaccines Viral Hemorrhagic Fevers Virus Western Blotting Work abstracting adeno-associated viral vector base clinical efficacy efficacy evaluation high risk immunoprophylaxis in vivo man mortality mouse model murine monoclonal antibody nonhuman primate optimism prophylactic public health emergency response

项目摘要

Summarty / Abstract Vectored immunoprophylaxis, or antibody gene transfer for infectious disease, is a promising new strategy to provide protection against high risk infectious agents, supplementing vaccine and passive immunization efforts. It has been demonstrated to be effective against HIV and Dengue virus in animal models, and there is currently an ongoing human trial for HIV prevention in high-risk individuals with an adeno-associated viral vector (AAV) delivering the gene for a broadly neutralizing HIV antibody. We propose to expand these efforts to the filoviruses, starting with the Ebolavirus Zaire (EBOV). EBOV causes severe hemorrhagic fever, with a high mortality between 30 and 90%, depending on the virus. Although the recent EBOV epidemic appears to be waning, the outbreak was classified by the WHO as "an international public health emergency." In addition, Ebolavirus is a potential bioterrorism agent (Category A). While recent reports suggest optimism for an Ebola vaccine, these are early trials with much work to be done to prove efficacy, and to characterize the onset of protection and durability. Passive immunization has shown great promise against EBOV in a therapeutic setting, however, production capabilities are not yet available for protection of a large segment of the population, and passive immunization requires repeated administration if used in a prophylactic setting. As such, there is an ongoing need for increasing the repertoire of immunoprotectants such as vectored antibodies.

摘要/摘要